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Introduction 
In response to an increased workload due to 
physiological or pathological stimuli, the heart 
may undergo a process of growth with increased 
muscle mass, the cardiac hypertrophy, in which 
the increase in weight is greater than 95% of the 
normal limit in relation to body weight and sex 
(1). 
The estimated prevalence of left ventricular 
hypertrophy in the population is around 16% (2). 
Cardiac hypertrophy is a unique mechanism of 
long term compensation used by the heart to 
adapt permanently to a greater workload. This 
may be due to a pressure overload (like in 
hypertensive patients and in people who practice 
power sports, such as weight lifting) or to a 
volume overload (like in endurance sports such as 
cycling, marathon, swimming or in the case of 
heart valve insufficiency) (3). 
Although representing a compensation 
mechanism, several studies showed that cardiac 
hypertrophy increases the cardiovascular 
morbidity and mortality (4,5). In early stage, it can 
maintain adequate cardiac function, but after a 
variable period of time may evolve to contractile 
dysfunction and heart failure (3). In fact, the 
peculiar and unusual structural, molecular and 
metabolic features of hypertrophic heart, that in 
the initial phase allow an increase of cardiac 
function, over a certain limit decrease the 
contractile efficiency and cause the evolution of 
hypertrophy in heart failure (6). The latter 
represents an important cause of death, presenting 
an annual mortality rate ranging between 10% and 
20% depending on its severity, reaching 30-40% at 
one year after the onset of symptoms (7). 
In this paper we report a rare case of extremely 
high degree of concentric cardiac hypertrophy 
(cardiomegaly) and a detailed analysis of the 
pathogenic mechanisms occurring in the 
determination of deadly event. 
Case report 
The case involved a 45 year old woman, in 
apparent good health. The body, with a length of 
about 170 cm and weighing about 90 kg 
(BMI=31.14), was in good general hygienic 
conditions. The body showed no signs of 
harmfulness and toxicological control was 
negative for common drugs of abuse. 
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The examination of the thanatological phenomena 
showed purple hypostasis in lower parts of the 
back, rising to the anterior axillary, and rigor 
mortis was present and more valid in the upper 
half of the body than in the bottom. 
To the opening we found the integrity of the 
diaphragm and bowel loops and the absence of 
fluid in the abdominal cavity. Following removal 
of the sternal plastron, at the level of the sternal 
head of the II-III rib, a non infiltrated transversal 
fracture was detected, as probable outcome of 
external cardiac massage, and pleural cavity was 
free from adhesions and dry. Pericardial cavity was 
free from adhesions with the presence of a few cc 
of serous fluid.  
The heart was significantly increased in shape and 
volume, with a weight of 1050 g and longitudinal 
diameter (LD) of 16.5 cm, transverse diameter 
(TD) of 16 cm and antero-posterior diameter 
(APD) of 9 cm (Figure 1), and on palpation the 
consistency was significantly increased. 
 
 
Fig. 1. Image of the heart: note the excessive size of 
diameters. 
 
The heart apex showed an important left 
ventricular hypertrophy, confirmed by the section 
of the rest of the organ, with a thickness of the 
left ventricle free wall of 4.2 cm, of the septum of 
4.3 cm and at the apex level of 3.5 cm, and a pale 
myocardium (boiled flesh-colored) (Figure 2). 
The papillary muscles were hypertrophic and 
chordae tendineae were slightly thickened. The 
valvular systems showed no alterations. To the 
opening of the coronary arteries according to 
cross sections of 1 cm, the walls were dilated with 
patent lumen. 
The lungs were increased in shape, volume and 
consistency (830 g the right and 800 g the left), 
with some petechiae in the interlobar fissures and 
sub crackling to palpation. Large, medium and 
small bronchi showed patent lumen and 
hyperemic mucosa and at the opening of vessels 
leakage of fluid blood. The full thickness section 
of the organs showed red and spongy cut surface, 
with frankly congested and edematous appearance, 
finding corroborated by the squeezing of the 
viscera with leakage of copious amounts of serum 
hematic  fluid, partially frothy. 
 
 
Fig. 2. Section at heart apex: note the significant 
thickening of ventricular walls with decrease in cavity 
radius. 
Discussion 
In literature the hypertrophic heart weights found 
in case of autopsy are variable. In a study on 
patients affected by hypertrophic cardiomyopathy, 
a genetic form of hypertrophy, the average heart 
weight was 530.0 ± 225.1 g and the average 
thickness of the interventricular septum was 2.25 
± 0.53 cm (8), while in a study on deceased obese 
patients the weight ranged between 450 g and 820 
g (average weight 619 g) and the wall thickness of 
the left ventricle between 1.5 and 3.0 cm (average 
thickness 2.0 cm) (9). In recent literature cases the 
heart weight ranged between 405 g (10) and 560 g 
(11). 
The severity of pathological hypertrophy and the 
heart weight (normal values: 250-300 g in women 
and 300-350 g in men, approximately between 
0.4% and 0.5% of body weight) depend on the 
basic pathological condition (usually 600 g in 
pulmonary hypertension and 800 g in systemic 
hypertension, aortic stenosis and mitral 
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regurgitation) (12). In rare cases of extreme 
pathological conditions (aortic regurgitation and 
hypertrophic cardiomyopathy) was found an 
exceptional increase in heart weight up to 1000 g 
and an increase in the diameter of individual 
muscle fibers (from 18 μ to 27 μ) (13). 
These data show that our case is an exceptional 
necropsy finding of cardiac hypertrophy, because 
the heart weight is 1050 g and the left ventricular 
walls thicknesses ranges between 3.5 and 4.2 cm, 
compared to values of the normal which ranges 
between 1.3 and 1.5 cm (12). 
Morphologically (shape of the heart) and in 
relation to the stimulus which supports the 
development, cardiac hypertrophy is distinguished 
in concentric and eccentric. In this case the 
macroscopic heart observation indicated the 
presence of a pathological left ventricular 
concentric hypertrophy. This anatomopathological 
feature is characterized by an increase in 
ventricular wall thickness (with reduction in the 
capacity of ventricular distention) and by the 
reduction of ventricular cavity radius (small 
ventricular cavity), with a consequent raise in the 
ratio between the two parameters, and individual 
cardiomyocytes show a greater enhancement in 
width compared to the length, with decrease in the 
length/width ratio (14). The thickness growth 
reduces stress on ventricular walls, allowing the 
heart to maintain  or  even  increase  the  function 
of pump, according  to  Laplace  law  (15),  
whereby wall  stress   (or tension)  is   an   inverse   
function   of  the wall thickness 
[tension=(pressure×radius)/(2×thickness)]. 
The pathological concentric hypertrophy is due to 
a chronic pressure overload, as occurs in 
hypertension or in cases of aortic and pulmonary 
valve stenosis (16). These pathological stimuli 
cause ventricular remodeling, dilatation and 
fibrosis, which result in the onset of the most 
frequent pathological cardiac hypertrophy (17), 
which differs from the physiological form for the 
specific structural and molecular characteristics. 
The pathologic cardiac hypertrophy, unlike the 
physiological, is only partially reversible upon 
cessation of the causing stimulus and after a 
variable period of time may become inadequate to 
maintain an efficient cardiac function and evolves 
in heart failure with an increased mortality (16). In 
fact, although both forms are characterized by 
cardiomyocytes enlargement, during pathological 
hypertrophy a modification of interstitial tissue, 
occurs with increase in the number of fibroblasts 
that synthesize excessive amounts of extracellular 
matrix proteins, particularly collagen, causing a 
marked interstitial fibrosis that does not occur in 
physiological form (18). This results in an increase 
in the rigidity of the walls, contributing to the 
onset of a initial diastolic and then systolic 
dysfunction in the hypertrophic heart. Previous 
alteration is associated with the growth of capillary 
network, which in pathological hypertrophy is not 
proportionate to the increase in myocardial mass 
(19). Even at the molecular level, studies have 
established the existence of differences between 
physiological and pathological hypertrophy. 
Unlike the latter, in pathological hypertrophy 
there is a stress-induced reactivation of the genes 
that encode the fetal isoforms of proteins, 
normally produced during the development 
process of the cardiac cells (20). The reactivation 
of fetal genetic program induces the production of 
larger amounts of some proteins, including the 
Atrial Natriuretic Peptide (ANP), B-type 
natriuretic peptide (BNP) and the fetal isoforms 
of contractile proteins (α-actin and β-myosin 
heavy chain, β-MHC), and decreased or altered 
production of adult proteins (α-myosin heavy 
chain protein and sarcoplasmic reticulum Ca2+-
ATPase) (16). Synthesis of contractile protein’s 
fetal isoforms allows a greater energy saving at the 
expense of reduced functionality, mainly due to 
lower consumption of ATP by the myosin’s fetal 
isoform. 
Finally at the metabolic level in the pathological 
hypertrophy there is a change of the metabolic 
substrates for the production of energy in the 
cardiomyocytes. During heart development, 
glycolysis is the major source of energy for muscle 
cells, while after birth the major metabolic 
pathway is the fatty acid oxidation, due to 
increased activity of mitochondria (21). In the 
pathological hypertrophic heart there is a return to 
a prevalent glycolytic metabolic profile (22). 
In the described case, the subject’s excessive 
weight (BMI=31.14) could lead one to suppose, as 
demonstrated by scientific evidence (23), the 
existence of hypertension that, by requiring a 
work overload, causes a left ventricular 
pathological hypertrophy, which is a risk factor 
for heart failure. Furthermore it was shown that 
the cardiomegaly is associated with the only 
presence of obesity indicators in the absence of 
arterial hypertension (24) and that it can be the 
leading factor of death in obese subjects. 
An anatomopathological feature of huge left 
ventricular hypertrophy, as the one described, 
implies a particularly high risk of progression to 
heart failure, compared to ones in which the 
degree of hypertrophy is lower (25).  In fact over a 
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certain limit, the structural, molecular and 
metabolic abnormal characteristics of cardiac 
hypertrophy influence heart’s contractile 
efficiency and causing progression to failure. 
The first hypothesized mechanism causing this 
evolution has been the loss of cardiomyocytes as a 
result of ischemic necrosis. This is primarily due 
to the decrease of the surface/volume ratio which 
causes a lower diffusion of metabolic substrates, 
especially oxygen, into the hypertrophic cells, 
influencing a low supply to the mitochondria in 
the center of cardiomyocytes with the consequent 
deficient energy production in the form of ATP, 
which, itself, results in depressed contractile 
efficiency (26). The insufficient development of 
the capillary network and the increased 
intercapillary distance contribute to insufficient 
supply of oxygen to the heart muscle cells. In fact 
the capillary growth does not proceed in 
proportion to the cardiomyocytes hypertrophy, 
causing the decrease of the oxygen diffusion 
through the myocardium (27). In addition, 
interstitial fibrosis of cardiac hypertrophy creates 
a barrier to the diffusion of metabolic substrates 
and oxygen to the muscle cells, contributing to 
ischemic necrosis and myocardial contractile 
insufficiency. 
Experimental observations have shown that 
autophagy can contribute to the loss of contractile 
myocardial cells. This process physiologically 
provides the renewal of cellular proteins, but in 
the hypertrophic cardiomyocytes proceeds at a 
high rate, leading to cell death (28). 
Some studies (29,30) suggest that cardiomyocyte 
apoptosis can participate to the transition from 
compensated hypertrophic phase to the onset of 
myocardial contractile deficit till to heart failure 
and death, through the loss of cardiac cells and 
their replacement by fibrous tissue. It is assumed 
that the continuous stimulation of cell growth 
induced by chronic work overload and the 
reactivation of the expression of fetal genes may 
induce an abortive response in the heart muscle 
cells and their apoptosis, because they are 
definitively differentiated and unable to progress 
in cell cycle up to the mitotic division (31). 
The loss of cells is accompanied by the onset of a 
pronounced interstitial fibrosis, due to the 
quantitative and qualitative abnormal 
accumulation of collagen, which determines a 
lower distensibility and an increased stiffness of 
the heart walls, leading to diastolic dysfunction 
that contributes to heart failure (16,18,32). 
The excessive heart weight, the pale myocardium 
(boiled flesh-colored) and greatly increased 
consistency show that the changes listed are 
present in our case, conditioning the contractile 
efficiency of the heart. 
In addition to previous mechanisms, the 
hypertrophic heart dysfunction is due to the 
change of the cardiomyocytes contractile 
characteristics, caused by the re-expression of 
fetal contractile proteins (eg β-MHC) and of the 
proteins regulating intracellular calcium 
homeostasis (sarcoplasmic reticulum Ca2+-
ATPase). The fetal isoforms of contractile 
proteins have a reduced efficiency in using ATP 
during contraction and this unfavorable 
bioenergetic profile plays an important role in 
hypertrophic heart dysfunction and in its 
evolution to heart failure (33). The sarcoplasmic 
reticulum Ca2+-ATPase play the fundamental 
function of restoring the normal cytosolic calcium 
concentration after the contraction, promoting the 
relaxation of actin and myosin filaments. During 
hypertrophic process, the decreased levels of 
production and activity of the Ca2 +-ATPase, due 
to abnormal gene expression, lead a slow removal 
of calcium ions and a compromise restore of their 
intracellular concentration to diastolic levels, 
causing a deficient diastolic relaxation and the 
onset of heart failure (34). 
Finally, because the heart is the organ which uses 
the greatest amount of energy (6 kg of ATP/day), 
it needs a constant supply to perform its 
contractile function. In course of cardiac 
hypertrophy in the mitochondria there is a switch 
from the fatty acid oxidation to a predominantly 
glycolytic metabolism. Due to the smaller amount 
of ATP per gram supplied by carbohydrates than 
to fatty acids, the switch causes an insufficient 
energy production to the needs of hypertrophic 
heart and makes the contraction process of the 
heart muscle cells less efficient, influencing the 
transition from compensate to decompensate 
hypertrophy (35). The lethal consequences can be 
myocardial infarction (36), rupture (37), 
haemopericardium (38) or arrhythmia (39) and 
their early diagnosis is very important. 
Cardiac hypertrophy is a compensatory 
mechanism of many diseases which cause a 
chronic work overload in the heart muscle, but at 
the same time is an important risk factor for death 
in patients who are affected. 
Although the occurrence of cardiac hypertrophy is 
quite frequent  at  the  autopsy, in  literature  heart  
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weights are lower than in our case, whose death 
can be attributed to the onset of heart failure in 
presence of a huge cardiomegaly. 
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